Dyne Therapeutics Inc. Common Stock (DYN)

About DYN

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

289

Website

www.dyne-tx.com

Fundamentals

1-day range

$25.3$25.93

Market cap

$4.71B

P/E (trailing)

—

P/E (forward)

-7.88

EPS (trailing)

$-3.26

Dividend yield

—

Beta

1.08

Avg. volume

2.23M

Forecasts

15 analyst ratings

Dyne Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• DYN

  Dyne Therapeutics Inc. Common Stock

  $25.07

  ▼ 3.91%
  Market cap $4.71BP/E —
  $11.65$27.31
• INDV

  Indivior Pharmaceuticals Inc. Common Stock

  $34.87

  ▼ 1.22%
  Market cap $4.66BP/E 12.77
  $22.22$42.81
• ACAD

  ACADIA Pharmaceuticals Inc. Common Stock

  $29.13

  ▼ 2.02%
  Market cap $4.39BP/E 12.85
  $19.69$30.96
• MANE

  Veradermics Incorporated Common Stock

  $97.53

  ▼ 4.20%
  Market cap $4.26BP/E —
  $32$131.24
• GRFS

  Grifols S.A. American Depositary Shares

  $7.68

  ▼ 1.79%
  Market cap $5.40BP/E 13.31
  $8.43$12.87
• VKTX

  Viking Therapeutics Inc. Common Stock

  $32.15

  ▼ 5.05%
  Market cap $3.80BP/E —
  $22.96$43.15
• PTCT

  PTC Therapeutics Inc. Common Stock

  $70.01

  ▼ 2.51%
  Market cap $5.68BP/E —
  $48.86$90.87

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $45
  Benzinga · 7/31/2026

• Jason P. Rhodes · July 7, 2026 · Sale

  5.0K @ $23.61
• Jason P. Rhodes · July 7, 2026 · Sale

  11.7K @ $23.62
• Jason P. Rhodes · July 7, 2026 · Sale

  49.2K @ $23.17
• Jason P. Rhodes · July 7, 2026 · Sale

  14.8K @ $23.62
• Jason P. Rhodes · July 7, 2026 · Sale

  62.5K @ $23.17
• Jason P. Rhodes · July 7, 2026 · Sale

  29.6K @ $23.62
• Jason P. Rhodes · July 7, 2026 · Sale

  124.4K @ $23.17
• Jason P. Rhodes · July 6, 2026 · Sale

  100.0K @ $22.79
• Jason P. Rhodes · July 6, 2026 · Sale

  127.2K @ $22.79
• Jason P. Rhodes · July 6, 2026 · Sale

  253.0K @ $22.79
• Erick Lucera · June 25, 2026 · Sale

  2.4K @ $20.37
• Jason P. Rhodes · June 25, 2026 · Sale

  5.0K @ $21.1
• Jason P. Rhodes · June 25, 2026 · Sale

  6.4K @ $21.1
• Jason P. Rhodes · June 25, 2026 · Sale

  12.7K @ $21.1
• Jason P. Rhodes · June 24, 2026 · Sale

  20.0K @ $21.02

Institutional Ownership

March 31, 2026

Total shares held

179.59M

Total value held

$2.64B

Institutional holders

221